Januvia 100 mg 28 tablets

Tradename

Januvia

Composition

Each tablet contains:

Sitagliptin 100 mg

Auxiliary components:

calcium hydrogen phosphate, unmilled; croscarmellose sodium; magnesium stearate; sodium stearyl fumarate.

Properties

Januvia@ (sitagliptin) is an orally active, highly selective inhibitor of the DPP-4 enzyme intended for the treatment of type 2 diabetes mellitus. peroxisome proliferator-activated receptors (PPAR-Y), alpha-glucosidase inhibitors, amylin analogs. By inhibiting DPP-4, sitagliptin increases the concentration of two hormones of the incretin family: GLP-I and GIP. Hormones of the incretin family are secreted in the intestine during the day, their concentration increases in response to food intake. Incretins are part of the internal physiological system of glucose homeostasi regulation.

Indications

Monotherapy: as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes;

Combination therapy: type 2 diabetes mellitus to improve glycemic control in combination with metformin or PPAR-Y agonists (for example, thiazolidinedione), when diet and exercise in combination with the listed agents alone do not lead to adequate glycemic control.

Method of administration and dosage:

Contraindications

Type 1 diabetes mellitus; diabetic ketoacidosis; pregnancy; lactation period (breastfeeding); children and adolescents under the age of 18; hypersensitivity to sitagliptin.

Precautions:

Use with caution in patients with renal insufficiency. In case of moderate and severe renal failure, as well as in patients with endstage renal failure who require hemodialysis, a dosage adjustment is required.

Side effects

upper respiratory tract infections, nasopharyngitis

headache

arthralgia